These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 3492396)

  • 1. Immunotherapy of murine sarcomas with interleukin 2. I. Local administration of human recombinant IL-2 preparations.
    Bubeník J; Indrová M; Toulcová A
    Folia Biol (Praha); 1986; 32(6):384-91. PubMed ID: 3492396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy of murine sarcomas with interleukin 2. II. Activation of killer cells by human recombinant IL-2.
    Indrová M; Bubeník J; Toulcová A
    Folia Biol (Praha); 1986; 32(6):392-8. PubMed ID: 3492397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The anti-tumour efficacy of human recombinant interleukin 2. Correlation between sensitivity of tumours to the cytolytic effect of LAK cells in vitro and their susceptibility to interleukin 2 immunotherapy in vivo.
    Bubeník J; Indrová M
    Cancer Immunol Immunother; 1987; 24(3):269-71. PubMed ID: 3496154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemoimmunotherapy of MC-induced mouse sarcomas with human recombinant interleukin 2 and cyclophosphamide: age-dependent decline of the therapeutic efficacy.
    Símová J; Bubeník J; Voitenok NN; Gren E
    Folia Biol (Praha); 1989; 35(3):137-42. PubMed ID: 2789150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-tumour efficacy of IL-1 and IL-2.
    Bubeník J; Indrová M; Holán V
    Folia Biol (Praha); 1988; 34(1):42-7. PubMed ID: 3260564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Local treatment with human recombinant interleukin 2 inhibits growth of MC-induced sarcomas in syngeneic mice.
    Bubeník J; Kieler J; Indrová M
    Folia Biol (Praha); 1986; 32(3):209-11. PubMed ID: 3488924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemoimmunotherapy in mice carrying HPV16-associated, MHC class I+ and class I- tumours: Effects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines.
    Indrová M; Bubeník J; Mikysková R; Mendoza L; Símová J; Bieblová J; Jandlová T; Jinoch P; Smahel M; Vonka V; Pajtasz-Piasecka E
    Int J Oncol; 2003 Mar; 22(3):691-5. PubMed ID: 12579325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic efficacy of repeated cycles of local IL-2 injections in mice carrying slowly growing tumour grafts.
    Símová J; Bubeník J; Indrová M; Bubeníková D; Jandlová T
    Folia Biol (Praha); 1993; 39(6):315-22. PubMed ID: 7926162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer immunotherapy using local interleukin 2 administration.
    Bubeník J; Indrová M
    Immunol Lett; 1987 Dec; 16(3-4):305-9. PubMed ID: 3502122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful immunotherapy of mouse melanoma and sarcoma with recombinant interleukin-2 and cyclophosphamide.
    Silagi S; Schaefer AE
    J Biol Response Mod; 1986 Oct; 5(5):411-22. PubMed ID: 3490544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma.
    Lafreniere R; Rosenberg SA
    J Immunol; 1985 Dec; 135(6):4273-80. PubMed ID: 3877766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic administration of cellular IL-10 induces an effective, specific, and long-lived immune response against established tumors in mice.
    Berman RM; Suzuki T; Tahara H; Robbins PD; Narula SK; Lotze MT
    J Immunol; 1996 Jul; 157(1):231-8. PubMed ID: 8683120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of minimal residual disease after surgery or chemotherapy in mice carrying HPV16-associated tumours: Cytokine and gene therapy with IL-2 and GM-CSF.
    Mikysková R; Indrová M; Símová J; Jandlová T; Bieblová J; Jinoch P; Bubeník J; Vonka V
    Int J Oncol; 2004 Jan; 24(1):161-7. PubMed ID: 14654953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intratumoral IL-12 gene transfer improves the therapeutic efficacy of IL-12 but not IL-19.
    Sobota V; Bubeník J; Símová J; Jandlová T
    Folia Biol (Praha); 2000; 46(5):191-3. PubMed ID: 11055798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy of cancer by systemic administration of lymphoid cells plus interleukin-2.
    Rosenberg SA
    J Biol Response Mod; 1984 Oct; 3(5):501-11. PubMed ID: 6389777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy, IL-12 gene therapy and combined adjuvant therapy of HPV 16-associated MHC class I-proficient and -deficient tumours.
    Indrová M; Bieblová J; Jandlová T; Vonka V; Pajtasz-Piasecka E; Reinis M
    Int J Oncol; 2006 Jan; 28(1):253-9. PubMed ID: 16328003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic interleukin-18 and low-dose interleukin-2 promote regression of established murine neuroblastoma in vivo.
    Redlinger RE; Mailliard RB; Lotze MT; Barksdale EM
    J Pediatr Surg; 2003 Mar; 38(3):301-7; discussion 301-7. PubMed ID: 12632339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant interleukin-2 acts as an adjuvant and helps to increase the efficacy of tumour vaccines.
    Vondrys P; Símová J; Takácová S; Jandlová T; Bubeník J
    Folia Biol (Praha); 1997; 43(1):39-40. PubMed ID: 9158948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic effects of combination therapy with human recombinant interleukin-2 and tumor necrosis factor in murine tumor models.
    Winkelhake JL; Stampfl S; Zimmerman RJ
    Cancer Res; 1987 Aug; 47(15):3948-53. PubMed ID: 3496953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy of cancer with lymphokine-activated killer cells and recombinant interleukin-2.
    Rosenberg SA; Mulé JJ
    Surgery; 1985 Sep; 98(3):437-44. PubMed ID: 3898451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.